UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  October 25, 2016

 

Diplomat Pharmacy, Inc.

(Exact Name of Registrant as Specified in its Charter)

 


 

Michigan
(State or Other Jurisdiction
of Incorporation)

 

001-36677
(Commission File Number)

 

38-2063100
(IRS Employer
Identification No.)

 

4100 S. Saginaw St.

Flint, Michigan 48507

(Address of Principal Executive Offices) (Zip Code)

 

(888) 720-4450

(Registrant’s Telephone Number, Including Area Code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

o                     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.02                                  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Appointment of Paul Urick and Employment Agreement

 

On October 25, 2016, Diplomat Pharmacy, Inc. (the “Company”) appointed Paul Urick to serve as the Company’s President, effective November 1, 2016.  Mr. Urick, age 45, has served as the Company’s vice president of industry relations, pharmaceutical account management, and payor strategy upon the Company’s acquisition of Burman’s Apothecary, L.L.C. (“Burman’s”) in June 2015, and was promoted to senior vice president in February 2016.  From September 2014 through the Company’s acquisition, Mr. Urick served as the president of managed markets and industry relations for Burman’s.  Prior to his service at Burman’s, beginning May 2011, Mr. Urick served as senior vice president of pharmacy operations for Cigna Corporation.  From 2004 until 2011, Mr. Urick served as senior vice president of pharmacy services at Independence Blue Cross.

 

On October 25, 2016, the Company and Mr. Urick entered into an employment agreement, effective November 1, 2016 (the “Urick Effective Date”) which provides that Mr. Urick will serve as President of the Company for an initial term of two years, and automatically extends for successive one-year periods unless either party gives at least 90 days’ notice prior to the end of the then existing term.

 

Mr. Urick’s base salary is $425,000, which amount will be reviewed at least annually and may be adjusted by the Company’s Board of Directors or the Compensation Committee (as appropriate, the “Administrator”), at its discretion.  He will be eligible for a cash bonus in 2016 and 2017, with a target amount of 60% of his annual base salary (pro rata for 2016). In 2018 and thereafter, Mr. Urick will be eligible for an annual cash bonus pursuant to programs generally applicable to senior executive officers of the Company.  Subject to Board approval (to be reviewed at the Board’s next regularly scheduled meeting), the Company will grant Mr. Urick options to purchase 100,000 of the Company’s common shares, at an exercise price equal to the closing price of the Company’s common stock on the grant date, vesting in equal annual installments over a four-year period.  In addition, Mr. Urick is eligible for equity compensation in 2017 at a target amount of 100% of his annual base salary.  In 2018 and thereafter, Mr. Urick will be eligible to participate in the then-existing equity compensation programs of the Company generally applicable to senior executive officers of the Company.  Mr. Urick also will be entitled to participate with other senior executive officers in any of the Company’s employee fringe benefit plans and he will be reimbursed for certain business expenses.

 

The employment agreement provides for certain benefits upon termination of Mr. Urick’s employment under certain circumstances, including a change of control of the Company, as defined therein.  If Mr. Urick’s employment is terminated by reason of death or disability, by the Company for cause or by Mr. Urick without good reason (in each case as defined in the employment agreement), Mr. Urick will receive earned but unpaid base salary through the termination date, plus any amounts specifically provided for under the Company’s employee benefit plans or as otherwise expressly required by applicable law (the “Accrued Benefits”).  If Mr. Urick is terminated by the Company other than for cause, or by Mr. Urick for good reason, Mr. Urick will receive a severance payment equal to six months of his annual base salary and the Accrued Benefits.  If, within one year following a change in control (as defined in the Company’s 2014 Omnibus Incentive Plan), Mr. Urick is terminated by the Company other than for cause, or Mr. Urick terminates for good reason, Mr. Urick will receive (i) 12 months of his annual base salary and the greater of his target bonus for the current year and the average annual bonus paid to him for the prior three full years (or any shorter period during which the he has been employed by the Company), payable in four equal quarterly installments during the one-year severance period, and (ii) the Accrued Benefits.  In addition, in the case of any termination, Mr. Urick’s rights with respect to any Company equity awards will be governed by the terms and provisions of the applicable plans and award agreements.

 

Mr. Urick’s bonus or incentive compensation is subject to clawback by the Company if the Company’s Board of Directors or a committee thereof determines that any fraud, negligence, or intentional misconduct by Mr. Urick is a significant contributing factor to the Company having to restate all or a portion of its financial statements and certain other specified conditions are satisfied.  The employment agreement contains customary confidentiality terms, as well as non-solicitation and non-competition provisions effective from the Urick Effective Date until the first anniversary following the termination date. If Mr. Urick violates any of the foregoing, the Company’s payment obligations under the employment agreement, including any severance payments, cease.  In addition, Mr. Urick must sign a general form of release of claims against the Company in order to be eligible for severance.

 

1



 

The foregoing summary is qualified in its entirety by reference to the employment agreement attached hereto as Exhibit 10.1 and incorporated herein by reference.

 

Resignation of Gary Kadlec

 

On October 25, 2016, the Company accepted the resignation of Gary Kadlec as the Company’s President.  He will continue as a Company employee until his retirement on December 31, 2016.  Mr. Kadlec also will continue to serve as a member of the Company’s Board of Directors (the “Board”) until his term expires at the Company’s 2017 annual meeting of shareholders.

 

Resignation of Sean Whelan and Severance Agreement

 

On October 25, 2016, the Company accepted the resignation of Sean Whelan as the Company’s Chief Financial Officer, Secretary and Treasurer, and a member of the Board, effective December 31, 2016.  The Company announced that Robin Johnson, vice president of finance and the chief financial officer of the Company’s specialty infusion division, will take on an expanded leadership role until a formal replacement has been appointed.

 

On October 25, 2016, the Company and Mr. Whelan entered into a severance agreement that sets forth the terms on which Mr. Whelan will resign effective December 31, 2016 (the “Whelan Effective Date”).

 

The severance agreement provides for a lump-sum severance benefit of $250,000 to be paid within 15 days of the Whelan Effective Date.  In addition, as of the Whelan Effective Date, 50,000 unvested options granted to Mr. Whelan on October 9, 2014 in connection with the Company’s initial public offering will vest and be immediately exercisable.  All other unvested options of Mr. Whelan will terminate immediately following the Whelan Effective Date.  The vested options held by Mr. Whelan (including those accelerated pursuant to the severance agreement) will be exercisable for a period of 180 days following the Whelan Effective Date.  The severance agreement also provides that the Company will continue group healthcare coverage for Mr. Whelan and his dependents from January 1, 2017 through March 31, 2017, subject to certain COBRA requirements.

 

The severance agreement contains a non-competition provision effective from the Whelan Effective Date until the first anniversary thereof. The severance agreement further contains a mutual general release of any claims for the benefit of Mr. Whelan and the Company.

 

The foregoing summary is qualified in its entirety by reference to the severance agreement attached hereto as Exhibit 10.2 and incorporated herein by reference.

 

A copy of the Company’s news release announcing the foregoing matters is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01                                            Financial Statements and Exhibits.

 

(d)                                  Exhibits

 

Exhibit No.

 

Description

 

 

 

10.1

 

Employment Agreement, dated October 25, 2016, by and between the Company and Paul Urick

 

 

 

10.2

 

Permanent Release and Severance Agreement, dated October 25, 2016, by and between the Company and Sean Whelan

 

 

 

99.1

 

Company news release dated October 25, 2016

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Diplomat Pharmacy, Inc.

 

 

 

 

 

 

By:

/s/ Philip R. Hagerman

 

 

Philip R. Hagerman

 

 

Chief Executive Officer

 

Date: October 26, 2016

 

3



 

EXHIBIT INDEX

 

Exhibit No.

 

Description

 

 

 

10.1

 

Employment Agreement, dated October 25, 2016, by and between the Company and Paul Urick

 

 

 

10.2

 

Permanent Release and Severance Agreement, dated October 25, 2016, by and between the Company and Sean Whelan

 

 

 

99.1

 

Company news release dated October 25, 2016

 

4


Exhibit 10.1

 

EMPLOYMENT AGREEMENT

 

This Employment Agreement (this “ Agreement ”) is made as of October 25, 2016, between Diplomat Pharmacy, Inc., a Michigan corporation (the “ Company ”), and Paul Urick (“ Employee ”).

 

WHEREAS, the Company wishes to retain Employee as its President and Employee wishes to accept employment with the Company under the terms and conditions set forth herein; and

 

WHEREAS, as a condition to the employment (or continued employment) of Employee with the Company, Employee is required to enter into this Agreement and to grant the covenants contained herein.

 

NOW THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

1.                                       Employment .  The Company shall employ Employee as its President, and Employee hereby accepts employment with the Company in such position, upon the terms and conditions set forth in this Agreement for the period beginning on November 1, 2016 (the “ Effective Date ”) and ending as provided in Section 5 hereof (the “ Employment Period ”).

 

2.                                       Definitions .  For purposes of this Agreement, the following terms shall have the following meanings:

 

(a)                                  Administrator” shall mean the Board or the Compensation Committee of the Board, consistent with Company policies and procedures in place from time to time.

 

(b)                                  Affiliate ” of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person. The term “control” (including the terms “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.

 

(c)                                   Board ” shall mean the board of directors of the Company.

 

(d)                                  Cause ” shall mean the Company’s good faith determination that one or more of the following has occurred with respect to the Employee: (1) the commission or conviction (including conviction upon of a plea of nolo contendere) of a felony or other crime which is punishable by imprisonment, (2) the commission of any act or omission involving dishonesty, fraud, or a violation of law with respect to the Company or any of its Subsidiaries or Affiliates, (3) reporting to work under the influence of alcohol or illegal drugs, the use of illegal drugs (whether or not at the workplace) or other conduct causing the Company or any of its Subsidiaries or Affiliates public disgrace, disrepute or economic harm, (4) repeated failure to perform any Employee’s duties as directed by the Board or the Chief Executive Officer,  (5)

 



 

breach of fiduciary duty, fraud or willful misconduct with respect to the Company and/or any of its Subsidiaries or Affiliates, or (6) any material breach of this Agreement or the Company’s policies and procedures by Employee.

 

(e)                                   Disability ” shall mean Employee’s inability to perform the essential functions of Employee’s position with the Company, with or without reasonable accommodations by the Company, for a period of 90 consecutive days or 120 days in any 365 day period.

 

(f)                                    Good Reason ” means the occurrence of any of the following without Employee’s written consent: (1) a material adverse change in Employee’s title, duties or responsibilities in a manner that is materially inconsistent with the position he holds; (2) a material reduction in Employee’s Base Salary; and (3) a material breach by the Company of its obligations, covenants or agreements under this Agreement.  The Company and Employee agree that “Good Reason” shall not exist unless and until Employee provides the Company with written notice of the acts alleged to constitute Good Reason within thirty (30) days of Employee’s knowledge of the occurrence of such event, and the Company fails to cure such acts within thirty (30) days of receipt of such notice, if curable.  Employee must terminate his employment within thirty (30) days following the expiration of such cure period for the termination to be on account of Good Reason.

 

(g)                                   Person ” means an individual, corporation, limited liability company, partnership, joint venture, association, trust, governmental entity, unincorporated organization or other entity.

 

(h)                                  Subsidiaries ” means, with respect to any Person, any corporation, partnership, limited liability company, association or other business entity of which (1) if a corporation, a majority of the economic interests or total voting power of shares of stock entitled to vote (irrespective of whether, at the time, stock of any other class or classes of such corporation shall have or might have voting power by reason of the happening of any contingency) in the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more of the other Subsidiaries of that Person or a combination thereof, or (2) if a partnership, limited liability company, association or other business entity, either (A) a majority of the partnership or other similar ownership interest thereof is at the time owned or controlled, directly or indirectly, by that Person or one or more Subsidiaries of that Person or a combination thereof, or (B) such Person is a general partner, managing member or managing director of such partnership, limited liability company, association or other entity.

 

3.                                       Position and Duties .

 

(a)                                  During the Employment Period, Employee shall serve as President and shall have such duties and responsibilities as are assigned to the Employee by the Board and the Chief Executive Officer consistent with the Employee’s position as President of the Company.

 

(b)                                  During the Employment Period, Employee shall, at all times, devote the substantial majority of Employee’s working time, attention, energies, efforts and skills to the

 

2



 

business and affairs of the Company and shall not, directly or indirectly, engage in any other business activity, whether or not for profit, gain or other pecuniary advantages, without the express written permission of the Board.  Employee shall perform Employee’s duties, responsibilities and functions to the Company hereunder to the best of Employee’s abilities in good faith and shall comply with all Company policies, rules and procedures.  In performing Employee’s duties and exercising Employee’s authority under this Agreement, Employee shall support and implement the reasonable and lawful business and strategic plans approved from time to time by the Board.

 

4.                                       Compensation and Benefits .

 

(a)                                  During the Employment Period, Employee’s shall receive an initial annual base salary (the “ Annual Base Salary ”) of $425,000.00, which shall be paid in accordance with the Company’s normal payroll practices for senior executive officers of the Company as in effect from time to time.  During the Employment Period, the Annual Base Salary shall be reviewed at least annually, and may be adjusted by the Administrator.  The term “Annual Base Salary” as utilized in this Agreement shall refer to the Annual Base Salary as so adjusted.

 

(b)                                  Employee shall be eligible for a cash bonus relating to the Company’s 2016 and 2017 fiscal year, with a target amount of 60% of Employee’s Annual Base Salary (prorated for the period beginning the Effective Date and ending December 31, 2016), with such actual amount to be determined consistent with the bonus plan in effect for other senior executive officers of the Company, on substantially the same terms and conditions as generally apply to such other officers, except that the size of the awards made to the Employee shall reflect the Employee’s position with the Company and such other factors as the Administrator reasonably determines from time to time.

 

(c)                                   In addition to the Annual Base Salary, for each fiscal year beginning January 1, 2018 and continuing through the Employment Period, the Employee shall be eligible for an annual cash bonus (the “ Annual Bonus ”) as determined by the Administrator.  Each such Annual Bonus awarded to the Employee shall be paid sometime during the first one hundred twenty (120) days of the fiscal year next following the fiscal year for which the Annual Bonus is awarded, unless the Employee shall elect, in compliance with Treasury Regulation 1.409A-2(a), to defer the receipt of such Annual Bonus; provided, that in any event, the Annual Bonus shall be paid during the year immediately following the fiscal year in which the bonus relates.  Employee must be employed with the Company in good standing on the payment date of the Annual Bonus to earn and be eligible to receive the Annual Bonus.

 

(d)                                  Subject to Board approval at its regularly-scheduled 2016 fourth quarter meeting (the “ Grant Date ”), Employee shall be granted options to purchase 100,000 of the Company’s Common Shares, at an exercise price equal to the closing price of the Company’s stock on the Grant Date on the New York Stock Exchange, vesting in equal annual installments over a four-year period.  Such grant shall be pursuant to an Option Award Agreement under the Plan, in form approved by the Administrator.

 

(e)                                   (i) For the period beginning January 1, 2017 through December 31, 2017, the Employee shall be eligible for equity compensation in an amount of up to 100% of the

 

3



 

Annual Base Salary; and (ii) for the period beginning January 1, 2018 and continuing through the Employment Period, the Employee shall be entitled to participate in any stock option, performance share, restricted stock unit or other equity based long-term incentive compensation plan, program or arrangement (the “ Plans ”) generally made available to senior executive officers of the Company; provided, that in the case of each of (i) and (ii) hereof, on substantially the same terms and conditions as generally apply to such other officers, except that the size of the awards made to the Employee shall reflect the Employee’s position with the Company and such other factors as the Administrator reasonably determines from time to time.

 

(f)                                    During the Employment Period, Employee shall receive such perquisites and fringe benefits and participate in all of the Company’s employee benefit programs and/or plans for which senior executive employees of the Company are generally eligible in accordance with the policies of the Company in effect from time to time.

 

(g)                                   During the Employment Period, the Company shall reimburse Employee for all reasonable out-of-pocket business expenses incurred by Employee in the course of performing Employee’s duties and responsibilities under this Agreement which are consistent with the Company’s policies, in effect from time to time, with respect to travel, entertainment and other business expenses, subject to the Company’s regular requirements with respect to reporting and documentation of such expenses.

 

(h)                                  If the Board, or an appropriate committee thereof, determines that any fraud, negligence, or intentional misconduct by the Employee is a significant contributing factor to the Company having to restate all or a portion of its financial statements, the Board or committee may require reimbursement of any bonus or incentive compensation paid to the Employee if and to the extent that (i) the amount of incentive compensation was calculated based upon the achievement of certain financial results that were subsequently reduced due to a restatement, (ii) the Employee engaged in any fraud or misconduct that caused or significantly contributed to the need for the restatement, and (iii) the amount of the bonus or incentive compensation that would have been awarded to the Employee had the financial results been properly reported would have been lower than the amount actually awarded.

 

5.                                       Term .  Employee’s employment with the Company will commence on the Effective Date and, subject to Section 6 , will continue until the second anniversary of the Effective Date (the “ Initial Term ”).  Following the Initial Term, the Employment Period will be automatically renewed for successive one-year periods, unless (i) otherwise terminated as set forth in Section 6(a)  of this Agreement, or (ii) the Company or Employee, as the case may be, sends the other party a written notice of non-renewal at least 90 days prior to the expiration of the Initial Term or any successive anniversary date thereof, as applicable.  The initial term of this Agreement, as it may be extended thereafter, is herein referred to as the “ Term .”  Notwithstanding anything contained in this Agreement to the contrary, the parties acknowledge and agree that Employee’s employment with the Company is on an at-will basis.

 

4



 

6.                                       Termination of Employment .

 

(a)                                  Termination .  Except for certain continuing obligations which the parties expressly agree survive termination, including, without limitation, Sections 6(d) , 7 , and 8 below, this Agreement and the Employment Period will terminate upon one of the following reasons:

 

(i)                                      Employee’s death or Disability;

 

(ii)                                   the termination by the Company at any time for Cause;

 

(iii)                                the termination by the Company at any time without Cause;

 

(iv)                               the resignation by Employee with Good Reason;

 

(v)                                  the resignation by Employee without Good Reason; and

 

(vi)                               the non-renewal of this Agreement by any party as contemplated pursuant to Section 5 .

 

(b)                                  Effect of Termination .  Except as otherwise expressly provided herein, all of Employee’s rights to salary, bonuses, employee benefits and other compensation hereunder which would have accrued or become payable after the termination of the Employment Period shall cease upon such termination, other than those expressly required under applicable law.  In all cases of termination set forth above in Section 6(a) : (i) Employee agrees to return to the Company and/or its Affiliates, as applicable, any business equipment (including but not limited to credit cards, computers, printers, fax machines and telephones) or other company property that Employee may have received from the Company or any Affiliate of the Company for use during Employee’s employment; and (ii) Employee will be deemed to have automatically resigned, effective as of the termination date, from any and all positions Employee holds as an officer, director, manager, and/or as a member of any governing body (or a committee thereof) of the Company or its Affiliates.

 

(c)                                   Termination other than without Cause or Resignation with Good Reason .

 

(i)                                      If the Employment Period is terminated for any reason other than pursuant to Section 6(a)(iii)  or Section 6(a)(iv)  above, Employee shall only be entitled to receive Employee’s Base Salary that has accrued through the date of termination of the Employment Period and shall not be entitled to any other salary, compensation or benefits from the Company or its Affiliates thereafter, except as otherwise specifically provided for under the Company’s employee benefit plans or as otherwise expressly required by applicable law (the “ Accrued Benefits ”); and

 

(ii)                                   the Employee’s rights with respect to any stock options, restricted stock units and/or other equity awards granted to the Employee by the Company shall be governed by the terms and provisions of the plans (including plan rules) and award agreements pursuant to which such stock options and equity awards were awarded, as in effect at the date the Employee’s employment terminated.

 

5



 

(d)                                  Termination without Cause or Resignation with Good Reason .

 

(i)                                      If the Employment Period is terminated pursuant to Section 6(a)(iii)  or Section 6(a)(iv)  above, then subject to compliance with Section 6(i)  below, in addition to the Accrued Benefits, the Company shall pay to Employee  an amount equal to six (6) months of Employee’s then current Base Salary over a period of six (6) months (the “ Severance Period ”), payable in equal installments in accordance with the Company’s regular payroll policies as if Employee’s employment had not ended (collectively, the “ Severance Payments ”).  Subject to compliance with Section 6(i)  below, the Severance Payments will commence on the first payroll date following the 30-day anniversary of the termination date, with the first payment being retroactive to the termination date.

 

(ii)                                   the Employee’s rights with respect to any stock options, restricted stock units and/or other equity awards granted to the Employee by the Company shall be governed by the terms and provisions of the plans (including plan rules) and award agreements pursuant to which such stock options and equity awards were awarded, as in effect at the date the Employee’s employment terminated.

 

(iii)                                Notwithstanding any other payment date or schedule provided in this Agreement to the contrary, if the Employee is deemed on the Termination Date of the Employee’s employment to be a “specified employee” within the meaning of that term under Section 409A of the Code and the regulations thereunder (“ Section 409A ”), then each of the following shall apply:

 

(A)                                With regard to any payment that is considered “nonqualified deferred compensation” under Section 409A and payable on account of and within six months after a “separation from service” (within the meaning of Section 409A and as provided in Section 6(h)  of this Agreement), such payment shall instead be made on the date which is the earlier of (1) the expiration of the six (6)-month period measured from the date of the Employee’s “separation from service,” and (2) the date of the Employee’s death (the “ Delay Period ”) to the extent required under Section 409A.  Upon the expiration of the Delay Period, all payments delayed pursuant to this Section 3(d) (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid to the Employee in a lump sum, and all remaining payments due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein; and

 

(B)                                To the extent that benefits to be provided during the Delay Period are considered “nonqualified deferred compensation” under Section 409A provided on account of a “separation from service,” the Employee shall pay the cost of such benefits during the Delay Period, and the Company shall reimburse the Employee, to the extent that such costs would otherwise have been paid or reimbursed by the Company or to the extent that such benefits would otherwise have been provided by the Company at no cost to the Employee, for the Company’s share of the cost of such benefits upon expiration of the Delay Period, and any remaining benefits shall be paid, reimbursed or provided by the Company in accordance with the procedures specified herein.

 

The foregoing provisions of this Section 6(d)(iii)  shall not apply to any payments or benefits that are excluded from the definition of “nonqualified deferred compensation” under Section 409A, including, without limitation, payments excluded from the definition of “nonqualified deferred

 

6



 

compensation” on account of being separation pay due to an involuntary separation from service under Treasury Regulation 1.409A-1(b)(9)(iii) or on account of being a “short-term deferral” under Treasury Regulation 1.409A-1(b)(4).

 

(iv)                               If, during the Employment Period and within one (1) year after a Change in Control, as defined in the Company’s 2014 Omnibus Incentive Plan, or any successor plan thereto, if the Employment Period is terminated pursuant to Section 6(a)(iii)  or Section 6(a)(iv)  above, then:

 

(A)                                the Company shall pay to the Employee the aggregate of the amount equal to (x) the Annual Base Salary, and (y) the greater of the target bonus for the then current fiscal year under the Plans or any successor annual bonus plan and the average annual bonus paid to or for the benefit of the Employee for the prior three (3) full years (or any shorter period during which the Employee has been employed by the Company); the Company shall provide the Employee the Accrued Benefits, and

 

(B)                                the Employee’s rights with respect to any stock options, restricted stock units and/or other equity awards granted to the Employee by the Company shall be governed by the terms and provisions of the plans (including plan rules) and award agreements pursuant to which such stock options and equity awards were awarded, as in effect at the date the Employee’s employment terminated.

 

(C)                                The amounts due under Section 6(d)(iv)(A)  above shall be payable in equal quarterly installments over a period of one year (collectively, the “ CIC Severance Payments ”); subject to compliance with Section 6(i)  below, the CIC Severance Payments will commence on the 30-day anniversary of the termination date, with the first payment being retroactive to the termination date.

 

(v)                                  If any payment or benefit (including payments and benefits pursuant to this Agreement) the Employee would receive in connection with a Change in Control from the Company or otherwise (the “ Payment ”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this paragraph, be subject to the excise tax imposed by Section 4999 of the Code (the “ Excise Tax ”), then the Company shall cause to be determined, before any amounts of the Payment are paid to the Employee, which of the following two alternative forms of payment shall be paid to the Employee: (A) payment in full of the entire amount of the Payment (a “ Full Payment ”), or (B) payment of only a part of the Payment so that Employee receives the largest payment possible without the imposition of the Excise Tax (a “ Reduced Payment ”).  A Full Payment shall be made in the event that the amount received by the Employee on a net after-tax basis is greater than what would be received by the Employee on a net after-tax basis if the Reduced Payment were made, otherwise a Reduced Payment shall be made.  If a Reduced Payment is made, (i) the Payment shall be paid only to the extent permitted under the Reduced Payment alternative, and the Employee shall have no rights to any additional payments and/or benefits constituting the Payment, and (ii) reduction in payments and/or benefits shall occur in the following order: (A) reduction of cash payments (in the reverse chronological order in which such cash would otherwise be paid); (B) cancellation of accelerated vesting of equity awards other than stock options; (C) cancellation of accelerated vesting of stock options (in the reverse chronological order in which such benefits would

 

7



 

otherwise be provided); and (D) reduction of other benefits paid to Employee.  In the event that acceleration of compensation from the Employee’s equity awards is to be reduced, such acceleration of vesting shall be canceled in the reverse order of the date of grant.

 

(e)                                   The independent registered public accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Change in Control, or a nationally recognized law firm, shall make all determinations required to be made under Section 6(d)(v) .  If the independent registered public accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company shall appoint a nationally recognized law firm or independent registered public accounting firm to make the determinations required hereunder.  The Company shall bear all expenses with respect to the determinations by such independent registered public accounting firm or law firm required to be made hereunder.

 

(f)                                    The independent registered public accounting firm or law firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to the Company and the Employee within fifteen (15) calendar days after the date on which Employee’s right to a Payment is triggered (if requested at that time by the Company or Employee) or such other time as requested by the Company or Employee.  Any good faith determinations of the accounting firm or law firm made hereunder shall be final, binding and conclusive upon the Company and Employee.

 

(g)                                   Conflict with Plans.   As permitted under the terms of the applicable Plans, the Company and the Employee agree that the definitions of Cause or Good Reason set forth in this Agreement shall apply in place of any similar definition or comparable concept applicable under the Plans (or any similar definition in any successor plan).

 

(h)                                  Section 409A.    It is intended that payments and benefits under this Agreement either be excluded from or comply with the requirements of Section 409A and the guidance issued thereunder and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted consistent with such intent.  In the event that any provision of this Agreement is subject to but fails to comply with Section 409A, the Company may revise the terms of the provision to correct such noncompliance to the extent permitted under any guidance, procedure or other method promulgated by the Internal Revenue Service now or in the future or otherwise available that provides for such correction as a means to avoid or mitigate any taxes, interest or penalties that would otherwise be incurred by the Employee on account of such noncompliance.  Provided, however, that in no event whatsoever shall the Company be liable for any additional tax, interest or penalty imposed upon or other detriment suffered by the Employee under Section 409A or damages for failing to comply with Section 409A.  Solely for purposes of determining the time and form of payments due the Employee under this Agreement (including any payments due under Section 6(d) ) or otherwise in connection with the Employee’s termination of employment with the Company, the Employee shall not be deemed to have incurred a termination of employment unless and until the Employee shall incur a “separation from service” within the meaning of Section 409A.  The parties agree, as permitted in accordance with the final regulations thereunder, a “separation from service” shall occur when the Employee and the Company reasonably anticipate that the Employee’s level of bona fide services for the Company (whether as an employee or an independent contractor) will permanently decrease to no more

 

8



 

than forty (40) percent of the average level of bona fide services performed by the Employee for the Company over the immediately preceding thirty six (36) months.  The determination of whether and when a separation from service has occurred shall be made in accordance with this subparagraph and in a manner consistent with Treasury Regulation Section 1.409A-1(h).  All reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirements that (i) any reimbursement is for expenses incurred during the Employee’s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement (and the in-kind benefits to be provided) during a calendar year may not affect the expenses eligible for reimbursement (and the in-kind benefits to be provided) in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred and (iv) the right to reimbursement (or in-kind benefits) is not subject to set off or liquidation or exchange for any other benefit.  For purposes of Section 409A, the Employee’s right to any installment payments under this Agreement shall be treated as a right to receive a series of separate and distinct payments.  Whenever a payment under this Agreement specifies a payment period with reference to a number of days ( e.g. , “payment shall be made within ninety (90) days following the date of termination”), the actual date of payment within the specified period shall be within the sole discretion of the Company.

 

(i)                                      Conditions to Severance Payments .  To be eligible for Severance Payments, Employee must meet the following conditions:

 

(i)                                      Within thirty (30) days following termination, Employee must return and continue to honor, an executed and irrevocable employment separation and release, in a form attached hereto as Exhibit A (the “ Release ”); and

 

(ii)                                   Employee must remain in compliance with Employee’s obligations under the Release, Sections 7 through 9 of this Agreement, and any other agreements between the Employee and the Company or its Affiliates or Subsidiaries.

 

Should Employee materially fail to comply with this Section, Employee shall receive no further benefits under this Agreement.

 

7.                                       Confidentiality; Non-Competition; Non-Solicitation; Non-Disparagement .

 

(a)                                  Employee acknowledges that the information, observations and data obtained by Employee while employed by the Company (prior to or after the date hereof) concerning the business or affairs of the Company or any of its Affiliates, including, without limitation, trade secrets, customer information, pricing information, financial plans, business plans, business concepts, supplier information, know-how and intellectual property and materials related thereto (the “ Confidential Information ”) shall be the property of the Company or such Affiliate.  Confidential Information shall not include information known to Employee prior to Employee’s employment with the Company, or information generally known in the industry.  Therefore, Employee agrees that Employee shall not disclose to any unauthorized person or use for Employee’s own purposes any Confidential Information without the prior written consent of

 

9



 

the Board, unless and to the extent that the disclosure of Confidential Information is made in response to a valid order of a court or other governmental body, or was otherwise required by law; provided , that, in such case, Employee shall be required to provide the Company prompt advance notice of any such disclosure and shall use commercially reasonable efforts to limit the extent of such disclosure.  Employee shall deliver to the Company at the termination of the Employment Period, or at any other time the Company may request, all memoranda, notes, plans, records, reports, computer tapes, printouts and software and other documents and data (and copies thereof) relating to the Confidential Information, Work Product (as defined below) or the business of the Company or any Affiliate which Employee may then possess or have under Employee’s control, whether physical or electronic, without retaining any copies of such materials.

 

(b)                                  Employee acknowledges that during Employee’s employment with the Company Employee has and will become familiar with the Company’s trade secrets and with other Confidential Information concerning the Company and its Affiliates and that Employee’s services shall be of special, unique and extraordinary value to the Company and its Affiliates.  Employee further acknowledges and agrees that the Company and its Affiliates would be irreparably damaged if Employee were to provide services to any Person competing with the Company or engaged in a similar business and that such competition by Employee would result in a significant loss of goodwill by the Company.  Therefore, in further consideration of the compensation to be paid to Employee hereunder and any other consideration paid to Employee under any other agreement with the Company, Employee agrees that during the period commencing on the date hereof and ending on the first anniversary of the date of termination of the Employment Period, Employee shall not, directly or indirectly, engage in Competition (as defined below).  The Employee shall be deemed to be engaging in “ Competition ” if he, directly or indirectly, anywhere in the continental United States where the Company conducts business or has plans to conduct business, owns, manages, operates, controls or participates in the ownership, management, operation or control of or is connected as an officer, employee, partner, director, consultant or otherwise with, or has any financial interest in, any business (whether through a corporation or other entity) engaged in any business activity that could be deemed to be competitive with one or more of the principal lines of business conducted by the Company or its Affiliates.  Ownership for personal investment purposes only of less than 2% of the voting stock of any publicly held corporation shall not constitute a violation hereof.

 

(c)                                   In further consideration of the compensation to be paid to Employee as described in Section 7(b)  above, for so long as Employee has continuing obligations under Section 7(b)  above, Employee shall not, directly or indirectly through another Person, (i) induce or attempt to induce any employee or consultant of the Company or any of its Affiliates to leave the employ or services of the Company or any of its Affiliates, or in any way interfere with the relationship between the Company or any of its Affiliates and any employee or consultant thereof, or (ii) solicit any customer of the Company or any of its Affiliates to provide products or services that compete with those offered (or for which there are specific plans to offer) by the Company or any of its Affiliates, to induce such customer to cease doing business with, or reduce the amount of business conducted with, the Company or its Affiliates, or in any way interfere with the relationship between any such customer and the Company or any of its Affiliates.

 

10



 

(d)           In further consideration of the compensation to be paid to Employee as described in Section 7(b)  above, for so long as Employee has continuing obligations under Section 7(b)  above, Employee shall not, in any communications with the press or other media or any communications with any customer, client, supplier or other current or prospective business relations of the other party, criticize, ridicule or make any statement which disparages or is derogatory to the Company, any of its Affiliates, or any of their shareholders, members, partners, directors, managers,  officers, employees, or agents of the Company or any of the Company’s Affiliates or Subsidiaries.

 

(e)           If, at the time of enforcement of the covenants contained in this Section 7 (the “ Restrictive Covenants ”), a court shall hold that the duration, scope or area restrictions stated herein are unreasonable under circumstances then existing, the parties agree that the maximum duration, scope or area reasonable under such circumstances shall be substituted for the stated duration, scope or area and that the court shall be allowed and directed to revise the restrictions contained herein to cover the maximum period, scope and area permitted by law.  Employee has consulted with legal counsel regarding the Restrictive Covenants and based on such consultation has determined and hereby acknowledges that the Restrictive Covenants are reasonable in terms of duration, scope and area restrictions and are necessary to protect the goodwill of the Company and its Affiliates, or the Employee in the case of Section 7(d) .

 

(f)            If Employee breaches any of the Restrictive Covenants, the Company shall have the following rights and remedies, each of which rights and remedies shall be independent of the others and severally enforceable, and each of which is in addition to, and not in lieu of, any other rights and remedies available to the Company at law or in equity: (i) the right and remedy to have the Restrictive Covenants specifically enforced by any court of competent jurisdiction (without posting a bond), it being agreed that any breach or threatened breach of the Restrictive Covenants would cause irreparable injury to the Company and its Affiliates and that money damages would not provide an adequate remedy to the Company, and (ii) the right and remedy to require Employee to account for and pay over to the Company and its Affiliates any profits, monies, accruals, increments or other benefits derived or received by Employee as the result of any transactions constituting a breach of the Restrictive Covenants.  In the event of any breach or violation by Employee of any of the Restrictive Covenants, the time period of such covenant with respect to such Person shall be tolled until such breach or violation is resolved.

 

(g)           Employee acknowledges that the obligations contained in this Section 7 are independent of any other obligations contained in this Agreement, such that they will remain in effect notwithstanding any claim by Employee that the Company has breached any other provision of this Agreement.

 

8.           Inventions and Patents .  Employee acknowledges that all discoveries, concepts, ideas, inventions, innovations, improvements, developments, methods, designs, analyses, drawings, reports, patent applications, copyrightable work and mask work (whether or not including any Confidential Information) and all registrations or applications related thereto, all other proprietary information and all similar or related information (whether or not patentable) which relate to the Company’s or any of its Affiliates’ actual or anticipated business, research and development or existing or future products or services and which are conceived, developed or

 

11



 

made by Employee (whether alone or jointly with others) while employed by the Company or any of its Affiliates, whether before or after the date of this Agreement (“ Work Product ”), belong to the Company or such Affiliate and Employee hereby assigns, and agrees to assign, all of the above Work Product to the Company or such Affiliate.

 

9.           Employee’s Representations .  Employee hereby represents and warrants to the Company that (i) the execution, delivery and performance of this Agreement by Employee does not and shall not conflict with, breach, violate or cause a default under any contract, agreement, instrument, order, judgment or decree to which Employee is a party or by which Employee is bound, (ii) Employee is not a party to or bound by any employment agreement, noncompete agreement or confidentiality agreement with any other Person or entity (other than such agreements that are being terminated hereby pursuant to Section 25 ), and (iii) upon the execution and delivery of this Agreement by the Company, this Agreement shall be the valid and binding obligation of Employee, enforceable in accordance with its terms.  Employee hereby acknowledges and represents that Employee has consulted with independent legal counsel regarding Employee’s rights and obligations under this Agreement and that Employee fully understands the terms and conditions contained herein.

 

10.        Survival Sections 6 through 25 shall continue to be in full force following the termination of the Employment Period.

 

11.        Notices .  All notices, requests, consents and other communications hereunder to any party shall be deemed to be sufficient if delivered in writing in person or by telecopy (or similar electronic means with a copy following by nationally recognized overnight courier) or sent by nationally-recognized overnight courier or first class registered or certified mail, return receipt requested, postage prepaid, addressed to such party at the address set forth below or at such other address as may hereafter be designated in writing by such party to the other parties.

 

Notices to Employee :

 

Paul Urick

412 Beaumont Circle

West Chester, PA  19380

 

Notices to the Company :

 

Diplomat Pharmacy, Inc.

4100 South Saginaw

Flint, MI 48507

Attn:       General Counsel

 

with a copy to:

 

Honigman Miller Schwartz and Cohn LLP

2290 First National Building

660 Woodward Avenue

Detroit, MI 48226

 

12



 

Telephone No: (313) 465-7392

Facsimile No: (313) 465-7393

Attn: Michael D. DuBay

 

or such other address or to the attention of such other person as the recipient party shall have specified by prior written notice to the sending party.  Any notice under this Agreement shall be deemed to have been given when so delivered, sent or mailed.

 

12.        Severability .  Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or any other jurisdiction, and this Agreement shall be construed and enforced in such jurisdiction to the maximum extent permitted by law.

 

13.        Complete Agreement .  This Agreement embodies the complete agreement and understanding among the parties with respect to the subject matter hereof and supersedes and preempts all prior understandings, agreements or representations by or among the parties or any Affiliate of the Company and Employee, written or oral, which may have related to the subject matter hereof in any way.

 

14.        No Strict Construction .  The language used in this Agreement shall be deemed to be the language chosen by the parties hereto to express their mutual intent, and no rule of strict construction shall be applied against any party.

 

15.        Counterparts .  This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and the same Agreement.  Facsimile counterpart signatures to this Agreement shall be binding and enforceable.

 

16.        Assignment .  Employee may not assign any of its rights or delegate any of Employee’s performance under this Agreement, except with the prior written consent of the Company (as approved by the Board and evidenced by a written consent), which may be withheld in the Company’s sole discretion.  The Company may assign this Agreement to any successor or assign (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company.  Any purported assignment of rights or delegation of performance by Employee in violation of this Section is void.

 

17.        Choice of Law .  All issues and questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by, and construed in accordance with, the laws of the State of Michigan, without giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Michigan, or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Michigan.   Any legal suit, action or proceeding arising out of or relating to this Agreement shall be instituted in the state or federal courts located in Michigan, and each party irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action or proceeding.  The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or proceeding in such court and agree not to plead or claim in any such court that any such suit,

 

13



 

action or proceeding brought in any such court has been brought in an inconvenient forum.  EACH PARTY HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVES ANY RIGHTS IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION BASED HEREON OR ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT.  THIS PROVISION IS A MATERIAL INDUCEMENT FOR THE PARTIES TO ENTER INTO THIS AGREEMENT.

 

18.        Amendment and Waiver .  The provisions of this Agreement may be amended or waived only with the prior written consent of the Company (as approved by the Board and evidenced by a written consent) and Employee, and no course of conduct or course of dealing or failure or delay by any party hereto in enforcing or exercising any of the provisions of this Agreement shall affect the validity, binding effect or enforceability of this Agreement or be deemed to be an implied waiver of any provision of this Agreement.

 

19.        Insurance and Indemnification .  The Company may, at its discretion, apply for and procure in its own name and for its own benefit life and/or disability insurance on Employee in any amount or amounts considered advisable.  Employee agrees to cooperate in any medical or other examination, supply any information and execute and deliver any applications or other instruments in writing as may be reasonably necessary to obtain and constitute such insurance.

 

20.        Taxes and Withholdings .  All payments made under this Agreement shall be made less applicable taxes and withholdings.  Notwithstanding any provision herein to the contrary, the Company makes no representations concerning Employee’s tax consequences under the Agreement under Section 409A of the Internal Revenue Code of 1986, as amended (“ Code ”), along with the rules, regulations and guidance promulgated thereunder by the Department of the Treasury or the Internal Revenue Service (collectively, “ Section 409A ”), or any other federal, state, or local tax law.  Employee’s tax consequences will depend, in part, upon the application of relevant tax law, including Code Section 409A, to the relevant facts and circumstances.  Employee should consult a competent and independent tax advisor regarding Employee’s tax consequences under the Agreement.

 

21.        Corporate Opportunities .  During the Employment Period, Employee shall submit to the Board all business, commercial and investment opportunities or offers presented to Employee or of which the Employee becomes aware which relate to the Company’s business at any time during the Employment Period.

 

22.        Employee’s Cooperation .  During and after the Employment Period, Employee shall cooperate with the Company and its Affiliates in any internal investigation or administrative, regulatory or judicial proceeding as reasonably requested by the Company (including, without limitation, Employee being available to the Company upon reasonable notice for interviews and factual investigations, appearing at the Company’s request to give testimony without requiring service of a subpoena or other legal process, volunteering to the Company all pertinent information and turning over to the Company all relevant documents which are or may come into Employee’s possession, all at times and on schedules that are reasonably consistent with Employee’s other permitted activities and commitments).  If the Company requires Employee’s cooperation in accordance with this Section, the Company shall reimburse Employee solely for

 

14



 

 reasonable out-of-pocket travel expenses (including reasonable lodging and meals, upon submission of receipts).

 

23.        Remedies .  Each of the parties to this Agreement shall be entitled to enforce its rights under this Agreement specifically, to recover damages caused by any breach of any provision of this Agreement and to exercise all other rights existing in its favor.  If the Company prevails in enforcing this Agreement, it shall be entitled to recover, in addition to other damages and remedies, its costs and reasonable attorneys’ fees.  The parties hereto agree and acknowledge that money damages would not be an adequate remedy for the other party’s breach of any term or provision of this Agreement and that the other party in its sole discretion may apply to any court of law or equity of competent jurisdiction (without posting any bond or deposit) for specific performance and/or other injunctive relief in order to enforce or prevent any violations of the provisions of this Agreement.

 

24.        Third-Party Beneficiaries .  Nothing herein, expressed or implied, shall create or establish any third party beneficiary hereto nor confer upon any Person not a party to this Agreement, any rights or remedies, including without limitation, any right to employment or continued employment for any specified period, of any nature or kind whatsoever, under or by reason of this Agreement.

 

25.        Termination of Former Agreements; Release .

 

(a)           The Company and Employee hereby agree that this Agreement supersedes and replaces, in its or their entirety, all current or former agreements or contracts that Employee has or had with the Company or any of its current or former Subsidiaries or Affiliates relating in any way to Employee’s employment, compensation, or other benefits (collectively, the “ Former Agreements ”), including, without limitation, any employment letters or employment agreements.  Employee further agrees that Employee is not entitled to any severance other than as provided in this Agreement.

 

(b)           EMPLOYEE ACKNOWLEDGES THAT EMPLOYEE HAS READ THIS AGREEMENT AND THAT EMPLOYEE FULLY KNOWS, UNDERSTANDS AND APPRECIATES ITS CONTENTS, AND THAT EMPLOYEE HEREBY EXECUTES THE SAME AND MAKES THIS AGREEMENT VOLUNTARILY AND OF EMPLOYEE’S OWN FREE WILL.

 

26.        No Offset .  Notwithstanding anything in this Agreement or in any other agreement between Employee and the Company or between Employee and any of the Company’s Affiliates to the contrary, there shall be no right of offset by the Company for any debts or obligations due to Employee by the Company or its Affiliates against any amounts due Employee hereunder.

 

(Signature page follows)

 

15



 

IN WITNESS WHEREOF, the parties hereto have executed this Employment Agreement as of the date first written above.

 

 

Company:

 

 

 

 

Diplomat Pharmacy, Inc.

 

 

 

 

 

 

_

By:

/s/ Philip R. Hagerman

 

 

Name: Philip R. Hagerman

 

 

Title: CEO

 

 

 

 

 

 

 

Employee:

 

 

 

 

 

 

 

/s/ Paul Urick

 

Paul Urick

 



 

Exhibit A

Form of Release

 

In consideration for certain payments or benefits paid or granted to the undersigned (the “ Former Employee ”) under Section  [6(d)] of the Employment Agreement, Former Employee hereby executes and delivers this Release (this “ Release ”) as of the date set forth on the signature page below.

 

WHEREAS , Former Employee and Diplomat Pharmacy, Inc., a Michigan Corporation (the “ Company ”) are party to that certain Employment Agreement, dated as of [ · ][ · ], 2016 (the “ Employment Agreement ”); and

 

WHEREAS , Former Employee’s employment relationship with the Company was terminated effective as of            , 201   (the “ Separation Date ”).

 

Now, therefore, for good and valuable consideration, the receipt and adequacy of which is acknowledged, Former Employee hereby agrees as follows:

 

I.                                         Former Employee understands that certain payments or benefits paid or granted to Former Employee under Section [ 6(d)] of the Employment Agreement represent, in part, consideration for signing this Release and are not salary, wages or benefits to which Former Employee was already entitled.  Former Employee understands and agrees that he will not receive certain of the payments and benefits specified in Section  [6(d)] of the Employment Agreement unless Former Employee executes this Release and does not revoke this Release within the time period permitted below or otherwise breach this Release.  Former Employee also acknowledges and represents that he has received all payments and benefits that he is entitled to receive (as of the date of this Release) by virtue of any employment by the Company.

 

II.                                    In consideration of and subject to the performance by the Company and, together with any direct or indirect subsidiaries of the Company (collectively, the “ Company Group ”), of its obligations under the Employment Agreement, Former Employee releases and forever discharges, as of the date of this Release, the Company Group and its affiliates and all present and former directors, managers, officers, agents, representatives, employees, successors and assigns of the Company Group and its affiliates and the Company Group’s direct or indirect owners including without limitation, Diplomat Pharmacy, Inc., a Michigan corporation and its affiliates, present and former directors, managers, officers, agents, representatives, employees, successors and assigns  (collectively, the “ Released Parties ”) to the extent provided below.  Except as provided in paragraph IV below and except for the provisions of the Employment Agreement which expressly survive the termination of Former Employee’s employment by the Company, Former Employee knowingly and voluntarily (for himself, his heirs, executors, administrators and assigns) releases and forever discharges the Company Group and the other Released Parties from any and all claims, suits, controversies, actions, causes of action, cross-claims, counter-claims, demands, debts, compensatory damages, liquidated damages, punitive or exemplary damages, other damages, claims for costs and attorneys’ fees, or liabilities of any nature whatsoever in law and in equity, both past and present (through the date this Release becomes effective and enforceable) and whether known or unknown, suspected, or claimed against the Company Group or any of the Released Parties which Former Employee, his spouse, or any of his heirs, executors, administrators or assigns, may have against the Company (including, but not limited to, any allegation, claim or violation, arising under: Title VII of the Civil Rights Act of 1964, as amended; the Civil Rights Act of 1991; the Age Discrimination in Employment Act of 1967, as

 



 

amended (the “ ADEA ”) (including the Older Workers Benefit Protection Act); the Equal Pay Act of 1963, as amended; the Americans with Disabilities Act of 1990; the Family and Medical Leave Act of 1993; the Worker Adjustment Retraining and Notification Act; the Employee Retirement Income Security Act of 1974; or their state or local counterparts; or under any other employment-related federal, state or local civil or human rights law, or under any other employment-related local, state, or federal law, regulation or ordinance; or under any public policy, contract or tort, or under common law; or arising under any employment-related policies, practices or procedures of the Company or any other member of the Company Group; or any claim for wrongful discharge, employment-related breach of contract, infliction of emotional distress, defamation; or any claim for costs, fees, or other expenses, including attorneys’ fees incurred in these matters) (all of the foregoing collectively referred to herein as the “ Claims ”).  Former Employee specifically represents that he has not filed any claims, charges, complaints, suits, or other actions against the Company or any other Released Party, with any federal, state or local agency or court.  Former Employee further agrees that should any claims, charges, complaints, suits or other actions be filed hereafter on his behalf by any federal, state or local agency or by any other person or entity, that he will immediately withdraw with prejudice, or cause to be withdrawn with prejudice, and/or dismiss with prejudice, or cause to be dismissed with prejudice, any such claims, charges, complaints, suits, or other actions filed against the Company or any other Released Party.  Former Employee agrees to opt-out of any class action filed against the Company or any other Released Party.

 

III.                               Former Employee represents that he has made no assignment or transfer of any right, claim, demand, cause of action, or other matter covered by paragraph II above.

 

IV.                                Former Employee agrees that this Release does not waive or release any rights or claims that Former Employee may have under the ADEA which arise after the date he executes this Release.  Former Employee acknowledges and agrees that his separation from employment with the Company in compliance with the terms of the Employment Agreement shall not serve as the basis for any claim or action (including, without limitation, any claim under the ADEA).

 

V.                                     Former Employee acknowledges that he has entered into this Release freely and without coercion, that he has been advised by the Company to consult with counsel of his choice, that Former Employee has had adequate opportunity to so consult, and that Former Employee has been given all time periods required by law to consider this Release, including but not limited to the 21-day period required by the ADEA.  Former Employee understands that he may execute this Release less than 21 days from its receipt from the Company, but agrees that such execution will represent his knowing waiver of such 21-day consideration period. Former Employee further acknowledges that within the 7-day period following his execution of this Release (the “ Revocation Period ”), Former Employee shall have the unilateral right to revoke this Release, and that the Company’s obligations under this Release shall become effective only upon the expiration of the Revocation Period without his revocation of this Release.  To be effective, notice of Former Employee’s revocation of this Release must be received by the Company on or before the last day of the Revocation Period.

 

VI.                                In signing this Release, Former Employee acknowledges and intends that it shall be effective as a bar to each and every one of the Claims mentioned or implied above in this Release.  Former Employee expressly consents that this Release shall be given full force and effect according to each and all of its express terms and provisions, including those relating to unknown and unsuspected Claims (notwithstanding any state statute that expressly limits the effectiveness of a Release of unknown, unsuspected and unanticipated Claims), if any, as well as those relating to any other Claims mentioned or implied above in this Release.  Former Employee acknowledges

 

2



 

and agrees that this waiver is an essential and material term of this Release and that without such waiver the Company would not have agreed to the terms of the Employment Agreement or this Release.  Former Employee further agrees that in the event he should bring a Claim seeking damages against the Company Group or any other Released Party, or in the event Former Employee should seek to recover against the Company Group or any other Released Party in any Claim brought by a governmental agency on his behalf, this Release shall serve as a complete defense to such Claims.  Former Employee has informed the Company of any pending charge or complaint of the type described in paragraph II as of the execution of this Release.

 

VII.                           Former Employee agrees that neither this Release, nor the furnishing of the consideration for this Release, shall be deemed or construed at any time to be an admission by any member of the Company Group, any Released Party or Former Employee of any improper or unlawful conduct.

 

VIII.                      Former Employee agrees that he will forfeit all amounts payable by the Company pursuant to the Employment Agreement or this Release if he challenges the validity of this Release.  Former Employee also agrees that if violates this Release by suing the Company Group or the other Released Parties for Claims, he will pay all costs and expenses of defending against such Claims, including reasonable attorneys’ fees, and return all payments received by Former Employee pursuant to this General Release.

 

IX.                                Former Employee agrees that this Release is confidential and agrees not to disclose any information regarding the terms of this Release, except to his immediate family and any tax, legal or other counsel he has consulted regarding the meaning or effect of this Release or as required by law, and he will instruct each of the foregoing not to disclose the same to anyone.

 

X.                                     Former Employee agrees to reasonably cooperate with the Company Group at the Company Group’s expense in any internal investigation, any administrative, regulatory, or judicial proceeding or any dispute with a third party.  Former Employee understands and agrees that his cooperation may include, but not be limited to, making himself available to the Company Group upon reasonable notice for interviews and factual investigations; appearing at the Company Group’s request to give testimony without requiring service of a subpoena or other legal process; volunteering to the Company Group pertinent information; and turning over to the Company Group all relevant documents which are or may come into Former Employee’s possession all at times and on schedules that are reasonably consistent with Former Employee’s other permitted activities and commitments, all at the Company’s expense.  Former Employee understands that in the event the Company Group asks for his cooperation in accordance with this provision, the Company will also reimburse him for reasonable travel expenses, (including lodging and meals), upon Former Employee’s submission of receipts.

 

XI.                                Former Employee acknowledges that the information, observations and data obtained by Former Employee concerning the business and affairs of the Company during the course of his employment with the Company were the property of the Company.  Former Employee agrees to abide by his post-employment obligations under the Employment Agreement, including but not limited to Section 7 thereof.

 

XII.                           Former Employee also understands that, notwithstanding anything in this Release to the contrary, nothing in this Release shall be construed to prohibit Former Employee from (y) filing a charge or complaint with the Equal Employment Opportunity Commission or any other federal, state or local administrative or regulatory agency, or (z) participating in any investigation or proceedings conducted by the Equal Employment Opportunity Commission or any other federal, state or local administrative or regulatory agency; however, former Employee expressly waives the right to any

 

3



 

individual relief of any kind in the event that the Equal Employment Opportunity Commission or any other federal, state or local administrative or regulatory agency pursues any claim on Former Employee’s behalf.  Notwithstanding the foregoing, Former Employee further understands that this Release does not prevent Former Employee from obtaining a whistleblower award from the Securities and Exchange Commission.

 

XIII.                      Notwithstanding anything in this Release to the contrary, this Release shall not relinquish, diminish, or in any way affect any rights or claims arising out of any breach by the Company Group or by any Released Party of the Employment Agreement or the Release after the date of this Release.

 

XIV.                       Whenever possible, each provision of this Release shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Release is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or any other jurisdiction, but this Release shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein.

 

BY SIGNING THIS RELEASE, FORMER EMPLOYEE REPRESENTS AND AGREES THAT:

 

I.                                         FORMER EMPLOYEE HAS READ IT CAREFULLY;

 

II.                                    FORMER EMPLOYEE UNDERSTANDS ALL OF ITS TERMS AND KNOWS THAT HE IS GIVING UP IMPORTANT RIGHTS, INCLUDING BUT NOT LIMITED TO, RIGHTS UNDER THE AGE DISCRIMINATION IN EMPLOYMENT ACT OF 1967, AS AMENDED, TITLE VII OF THE CIVIL RIGHTS ACT OF 1964, AS AMENDED; THE EQUAL PAY ACT OF 1963, THE AMERICANS WITH DISABILITIES ACT OF 1990; AND THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974, AS AMENDED;

 

III.                               FORMER EMPLOYEE VOLUNTARILY CONSENTS TO EVERYTHING IN THIS RELEASE;

 

IV.                                FORMER EMPLOYEE HAS BEEN ADVISED TO CONSULT WITH AN ATTORNEY BEFORE EXECUTING IT AND FORMER EMPLOYEE HAS DONE SO OR, AFTER CAREFUL READING AND CONSIDERATION, FORMER EMPLOYEE HAS CHOSEN NOT TO DO SO OF HIS OWN VOLITION;

 

V.                                     FORMER EMPLOYEE HAS SIGNED THIS RELEASE KNOWINGLY AND VOLUNTARILY AND WITH THE ADVICE OF ANY COUNSEL RETAINED TO ADVISE FORMER EMPLOYEE WITH RESPECT TO IT; AND

 

VI.                                FORMER EMPLOYEE AGREES THAT THE PROVISIONS OF THIS RELEASE MAY NOT BE AMENDED, WAIVED, CHANGED OR MODIFIED EXCEPT BY AN INSTRUMENT IN WRITING SIGNED BY AN AUTHORIZED REPRESENTATIVE OF THE COMPANY AND BY FORMER EMPLOYEE.

 

4



 

Former Employee executes this Release as of             , 20  .

 

 

 

Name:                                         

 

 


Exhibit 10.2

 

PERMANENT RELEASE

AND

SEVERANCE AGREEMENT

 

This Permanent Release and Severance Agreement (“Agreement”) is entered into, as of the last date of execution by the parties, by and between Diplomat Pharmacy, Inc. and its affiliated entities (collectively the “Company”) and Sean Whelan (“Employee”).  For purposes of this Agreement, the Company includes its past and present successors, assigns, divisions, departments, parents, subsidiaries, related or affiliated entities, and all current or former officers, directors, shareholders, members, benefit plans, attorneys, employees and agents in their capacities as such, including, without limitation, any and all management, administrative, or supervisory employees in their capacities as such.

 

RECITALS

 

WHEREAS, Employee was an at-will employee employed as the Chief Financial Officer by the Company and also serves as a member of the Company’s Board of Directors (the “Board”); and

 

WHEREAS, Employee and Company have mutually agreed to terminate the Employee’s employment with the Company effective December 31, 2016, and Employee has agreed to resign as a member of the Board effective as of such date (the “Last Day of Employment”); and

 

WHEREAS, Employee agrees to waive recovery of any damages and other claims relating to or arising out of employment with the Company or the separation there from, in consideration for the agreements herein, as well as for the severance benefits set forth in this Agreement to which Employee is not otherwise entitled; and

 

WHEREAS, the Company agrees to provide the severance benefits specified herein, which Employee is not otherwise entitled to receive, in exchange for the promises set forth in this Agreement; and

 

WHEREAS, the Company has obtained all necessary approvals of the Company’s Board of Directors to perform its obligations to Employee specified herein;

 

NOW, THEREFORE, in consideration of the foregoing and of the terms, conditions and agreements hereinafter set forth, the Company and Employee agree as follows:

 

1.               Consideration Paid to Employee . In exchange for Employee executing this Agreement and provided it is not revoked as provided herein, the Company shall pay or provide to Employee the following consideration, which Employee acknowledges is extra and in addition to benefits Employee is otherwise entitled to receive:

 

a.               Within fifteen (15) days of the later of (i) the Last Day of Employment or (ii) expiration of the Employee’s right of revocation and in accordance with the next

 

1



 

scheduled payroll date thereafter, the Company will pay to Employee a lump-sum severance benefit of Two Hundred Fifty Thousand Dollars ($250,000.00). All severance payments shall be subject to applicable state and federal or other lawful withholdings.  It is understood that the Company will not be withholding or making any 401K contributions on the severance payments, since Employee will no longer be employed with the Company.  Employee shall not be entitled to any payments until Company has received a fully executed original of this Agreement and the seven-day revocation period described in Paragraph 4 has expired without Employee exercising the right to revoke.

 

b.               Immediately following the Last Day of Employment, and notwithstanding any terms of any Option Award Agreement to the contrary, 50,000 of the unvested options granted to Employee on October 9, 2014, shall vest and be immediately exercisable.

 

c.                All other unvested options from Employee’s 2015 and 2016 annual equity awards shall terminate immediately following the Last Day of Employment, in accordance with Section 6(i) of the Company’s 2014 Omnibus Incentive Plan (the “2014 Plan”) and the applicable award agreements issued thereunder.

 

d.               Notwithstanding any terms to the contrary in Section 6(i)(iv) of the 2014 Plan and, as applicable, Section 8(c) of the Company’s 2007 Option Plan (the “2007 Plan”), each of Employee’s vested options (including the options accelerated under Paragraph 1.b. above) shall terminate 180 days after the Last Day of Employment.

 

e.                On the Last Day of Employment, Company shall have caused its stock transfer agent (at the time of execution of this Agreement, Computershare Limited) to implement the benefits, set forth in Paragraphs 1.b and 1.d above, in Employee’s account with said stock transfer agent.

 

f.                 The Company shall continue group healthcare coverage for Employee and any dependents through March 31, 2017.  Provided Employee makes a timely election for continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), for the period from January 1, 2017 to March 31, 2017, Employee shall pay and Company shall reimburse the required premium to continue this coverage.  To receive reimbursement, Employee shall submit an invoice to Company, such invoice shall be addressed to: Diplomat Pharmacy, Inc. Attn: Senior Director of Human Resources, 4100 S. Saginaw, Flint, MI 48507.  After March 31, 2017, if Employee elects to remain under the Employer’s group health insurance plan consistent with Employee’s rights under COBRA, Employee shall be required to pay the required premium to the Company to continue this coverage for the COBRA continuation rights period. Employee will receive separate notice of COBRA rights pursuant to the Company’s normal practice.

 

2



 

2.               Entire Amount of Consideration .   Employee is not otherwise entitled to the consideration described in Paragraph 1 and the consideration is sufficient to support the covenants and promises by Employee in this Agreement.  Employee further agrees not to seek any further compensation from the Company for any claimed damages, costs, or attorneys’ fees in connection with the matters encompassed in this Agreement or any other claims.

 

3.               General Release of All Claims by Employee .  Except for the rights and obligations expressly set forth herein, Employee, for Employee and for each of Employee’s past and present agents, assigns, transferees, heirs, spouses, relatives, executors, attorneys, administrators, employees, predecessors, affiliates, successors, insurers, and representatives in their capacities as such (“Releasors”), hereby releases and discharges the Company and its respective past and present agents, assigns, transferees, attorneys, administrators, officers, directors, stockholders, employees, predecessors, subsidiaries, parents, affiliates, successors, insurers, and representatives in their capacities as such (“Releasees”) from any and all claims and causes of action, known or unknown, which Releasors now have or may have against any of the Releasees arising through the date of this Agreement, including but not limited to claims arising out of or relating to Employee’s employment or the severance of Employee’s employment from the Company.  This release is intended to be interpreted broadly and is intended to include, without limitation, all common law claims (including but not limited to: breach of contract, breach of the covenant of good faith and fair dealing, wrongful discharge in violation of public policy, infliction of emotional distress, negligence, invasion of privacy, interference with contractual relationship, defamation and fraud), claims based on the Company’s incentive and/or compensation plans, as well as any statutory claims (including but not limited to claims arising under: the Age Discrimination in Employment Act (“ADEA”) as amended, 29 U.S.C. § 621 et seq. , as amended, 29 U.S.C. § 621, et seq. and as amended by the Older Workers Benefit Protection Act of 1990; Executive Order 11246; the Rehabilitation Act of 1973; Title VII of the Civil Rights Act of 1964, as amended by the Civil Rights Act of 1991, 42 U.S.C. § 2000 et seq. ; the Civil Rights Act of 1866, 42 U.S.C. § 1981; the Family and Medical Leave Act of 1993, 29 U.S.C. § 2601 et seq. ; the Americans with Disabilities Act of 1990, 42 U.S.C. § 12101 et seq. ; ; the Reconstruction Era Civil Rights Acts, 42 U.S.C. Sections 1981-1988; the Civil Rights Act of 1994; Employee Retirement Income Security Act of 1974, the Worker Adjustment and Retraining Notification Act, 29 U.S.C. § 2102 et seq. , as well as claims under  any other federal, state of Michigan, or local laws or regulations of any kind, or any other claim whatsoever arising out of Employee’s employment or the termination of Employee’s employment, other than those that cannot be released as a matter of law.  This release shall not be interpreted to require Employee to waive or release Employee’s right to file a charge with the Equal Employment Opportunity Commission (“EEOC”) or the National Labor Relations Board (“NLRB”).  This release also does not apply to any lawsuit brought to challenge the validity of this Agreement under the ADEA, to enforce the terms of this Agreement, or for claims that arise under the ADEA after the Effective Date.  Employee and the Company expressly acknowledge and agree that neither the Company nor Employee would enter into this Agreement but for the representation and warranty that Employee is hereby releasing any and all claims of any nature whatsoever, known or unknown, whether statutory or at common law, which Employee now has or

 

3



 

could assert directly or indirectly against any of the Releasees (other than as expressly set forth herein).

 

Notwithstanding the foregoing, Employee is not releasing or waiving any claim (a) for the sole purpose of enforcing Employee’s rights under this Agreement, or (b) to enforce Employee’s post-employment rights under any tax qualified employee retirement plan then maintained by the Company.

 

4.               General Release of All Claims By The Company. The Company hereby releases and discharges Employee from any and all causes of action, liability and claims of every kind, known or unknown, fixed, vested or contingent, relating to or arising in any way from any act or omission of Employee during the course of his employment with the Company.

 

5.               Waiver and Release of Claim for Age Discrimination .  Employee acknowledges that Employee is forty (40) years of age or older. Employee intends and does hereby waive, release and forever give up any recovery of damages for violations of Employee’s rights under the Age Discrimination in Employment Act (“ADEA”), as amended. The ADEA is a federal law that protects Employee’s employment rights by making it unlawful for an employer to discriminate against Employee because of Employee’s age.

 

a.               Employee is advised to consult with an attorney prior to signing this Agreement releasing any claim for age discrimination. Employee understands that whether or not to do so is Employee’s decision.

 

b.               Employee acknowledges that Employee was advised that Employee had twenty-one (21) days to consider this Agreement before signing it, but could sign it earlier if Employee freely and voluntarily chose to do so, and that no change to this Agreement, whether material or immaterial, will restart the running of this twenty-one (21) day review period.

 

c.                Employee further acknowledges that Employee has seven (7) days after signing this Agreement to change Employee’s mind and revoke the Agreement.  To be effective, any revocation must be in writing and either (i) mailed to Diplomat Pharmacy, Inc., Attn: General Counsel, 4100 S. Saginaw, Flint MI 48507, and postmarked within seven (7) days from the date on which Employee signed this Agreement, or (ii) hand delivered to the Company within seven (7) days from the date on which Employee signed this Agreement.  If revocation is made by mail, mailing by certified mail return receipt requested is required as proof of mailing.  Employee acknowledges that the Company provided ample opportunity to ask questions, obtain information, and seek understanding regarding the waiver and release of Employee’s protections from age discrimination. Employee affirms that the Company did not pressure, coerce, or threaten Employee to obtain the execution of this Agreement. Employee entered into this Agreement of Employee’s own free will, knowingly, and only after careful deliberation and forethought.  Employee acknowledges that the consideration paid for this

 

4



 

Agreement, as provided in Paragraph 1, is extra and in addition to those amounts to which Employee was otherwise entitled.

 

6.               No Admission of Liability . The Company and Employee agree that neither the negotiations nor the signing of this Agreement shall constitute an admission by the Company that it has acted wrongfully with respect to Employee or any other person or that Employee has any rights whatsoever against the Company.  The Company specifically disclaims any liability to, or wrongful acts against, Employee or any other person, on the part of itself, its directors, officers, employees, and agents, and Employee disclaims any liability to or wrongful or unlawful conduct against the Company.  Employee further agrees that he or she will not state, represent, suggest, or imply to anyone that the Company is liable or at fault or has admitted liability or any wrongful acts affecting Employee.

 

7.               Confidentiality .

 

a.               Employee acknowledges that during the course of his employment with the Company, Employee acquired knowledge of and had access to: (1) confidential information belonging to the Company, (2) proprietary information belonging to the Company, (3) trade secrets of the Company, (4) other information which was disclosed to the Company on a confidential basis, and (5) material non-public information concerning the Company’s business and financial condition (collective the “Company Information”).  Employee agrees, following Employee’s last day of employment with the Company, he or she will not, directly or indirectly, make use of or disclose any Company Information to any individual who is not either employed by or retained by the Company without the consent of the Company.  Notwithstanding the proceeding sentence, Employee may disclose Company Information in response to a demand for disclosure contained in a subpoena or in discovery proceedings concerning a matter before an administrative or judicial proceeding if such disclosure is, in the reasonable opinion of legal counsel for Employee, required by applicable law; provided Employee shall provide the Company notice of such demand as soon as is reasonably feasible after receiving the demand and consulting with legal counsel and shall cooperate with any effort by the Company to bar discovery or disclosure of the Company Information through a protective order or injunctive relief.  Employee’s duty to cooperate does not require that he incur any cost or expense in furtherance of the Company’s effort to bar discovery or disclosure and does not require that he violate or ignore a lawfully entered order of a court.  Company agrees to indemnify and hold harmless Employee from any liability, cost or expense that he may incur as the result of Company’s efforts to bar disclosure or discovery of the Company Information.

 

b.               In addition to all other remedies provided in law or equity, the provisions of this Paragraph 7 may be enforced through an independent action for an injunction and/or to recover from Employee all consideration provided for in Paragraph 1.

 

5



 

c.                Employee understands and acknowledges that failure to comply with this Paragraph 7 will be deemed a material breach of this Agreement and shall entitle the Company to pursue all remedies provided in law or equity and shall require Employee to repay all money paid to Employee pursuant to this Agreement.

 

8.               Covenant not to Compete .  Employee acknowledges that Employee has become familiar with Company Information.  Employee further acknowledges and agrees that the Company and its subsidiaries and affiliates would be irreparably damaged if Employee were to provide services to any person competing with the Company or any of its subsidiaries or affiliates or engaged in a similar business and that such competition by the Employee would result in a significant loss of goodwill by the Company and its subsidiaries or affiliates. Therefore, in further consideration of the benefits provided in Paragraph 1, Employee agrees that until the first anniversary of the date of this Agreement (the “Restricted Period”), Employee shall not directly, either for himself or through or for any other person, own any interest in, manage, control, participate in (including any direct or indirect interest in any enterprise, whether as an officer, director, manager, employee, partner, equity holder, member, agent, representative, shareholder, partner, joint venturer, franchisor, franchisee or otherwise) consult with, or render services to or for, any person that is in any business which competes with any business that the Company and/or its affiliates or subsidiaries conduct or has specific plans to conduct at the end of the Restricted Period, in any foreign jurisdiction in which the Company or any of its affiliates has operations or anywhere in the United States; provided, however, that the foregoing shall not restrict Employee from passively owning less than two percent (2%) of the stock of a publicly held corporation so long as neither Employee nor any of his affiliates has any active participation in the business of such corporation; and provided further, nothing in this Agreement shall prevent Employee from seeking and becoming employed by a pharmaceutical manufacturer or in non-specialty retail pharmacy, long-term care, hospital pharmacy or any other non-competing pharmacy.

 

9.               Company Property . Employee warrants and represents, that before Company is obligated to pay any consideration pursuant to Paragraph 1of this Agreement, Employee shall return to the Company all Company Information and all other Company property including, without limitation, Company reports, files, memoranda, records, software, credit cards, door and file keys, computer access codes, disks, and instructional manuals, and other physical or personal property which Employee received, prepared, or helped to prepare in connection with his employment with the Company, and that he will not retain any copies, duplicates, reproductions, or excerpts thereof.  Employee also agrees to provide the Company with all computer passwords necessary to access computer-stored Company Information.

 

10.        Duty to Cooperate .  Employee agrees to voluntarily cooperate with and provide any requested information to the Company or its legal representatives in connection with the Company’s defense of any claims, charges, or lawsuits currently pending or asserted in the future against the Company.  This shall include making Employee available to meet with the Company’s legal representatives and appearing to testify truthfully as a witness

 

6



 

in administrative or court proceedings or in depositions when requested by the Company.  The Company agrees to reimburse Employee for all reasonable travel expenses, lost wages and attorney’s fees and costs incurred by Employee as a result of Employee’s cooperation with the Company’s legal representatives.

 

11.        Indemnification.  The Company agrees to defend and indemnify Employee for any and all claims or causes of action brought against Employee by a third party arising out of or in connection with his employment with the Company, provided that Company is not obliged to indemnify Employee in connection with any judgment entered against him based upon Employee’s gross negligence, intentional misconduct, fraud, or criminal misconduct.  Employee may select counsel to defend the claim or cause of action and shall notify the Company of any such claim or cause of action within ten (10) days of his knowledge of such claim or cause of action.  Company is not obliged to reimburse Employee for any costs of defense incurred prior to its receipt of notice of the claim or cause of action and is not obliged to indemnify Employee against any loss or liability under this paragraph if it receives notice after the ten (10) day period and the defense of the claim or cause of action was materially prejudiced by such delayed notice.

 

12.        Non-Disparagement .

 

a.               Employee represents and warrants that he or she shall refrain from any action that materially harms the reputation or goodwill of the Company, including its subsidiaries or affiliates and any of its officers, directors, employees, agents or shareholders, including, but not limited to, making derogatory comments to the Company’s employees, lenders, suppliers, customers, and others in the trade about the character and ability of the Company’s directors, officers, executives, employees, representatives and agents, and the manner in which the Company conducts its business.  The Company represents and agrees that persons then serving as an officer or director of the Company shall refrain from any action that materially harms the reputation or goodwill of Employee, including but not limited to making derogatory comments to the Company’s employees, lenders, shareholders, suppliers, customers, and others in the Company’s trade about the character and ability of Employee or regarding the manner in which Employee carried out his duties or otherwise performed on behalf of the Company.  This sub-section shall not be construed to prohibit or to limit any statements made by Employee to the EEOC or any other state or federal agency in the course of participating in any agency proceeding.

 

b.               Each party understands and acknowledges that failure to comply with this Paragraph 12 will be deemed a material breach of this Agreement, and shall entitle the non-breaching party to all remedies provided in law or equity.

 

13.        No Reemployment . Employee agrees not to apply or reapply for employment at any time in the future with, or provide any personal services to or for the Company or any of the entities covered as a releasee, and Employee agrees that this Permanent Release and

 

7



 

Severance Agreement shall be sufficient grounds and a legitimate, non-discriminatory basis alone to reject any such application.

 

14.        Applicable Law .  This Agreement shall be governed by and construed in accordance with the laws of the State of Michigan. By execution hereof, Employee hereby waives any right he or she may have to arbitration as against the Company, and, as to any dispute with regard to this Agreement, Company and Employee hereby submit to the jurisdiction of the state and federal courts located in the State of Michigan.

 

15.        Severability of Provisions .  Should any provision of this Agreement be declared or be determined by any court to be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be affected thereby and said illegal part, term or provision shall be deemed not to be a part of this Agreement.

 

16.        Remedies for Breach .  In addition to any right to damages the non-breaching party may have, the non-breaching party shall have the right to seek injunctive relief.

 

17.        Miscellaneous Provisions .

 

a.               This Agreement contains the entire agreement between the Company and Employee with respect to the subject matter hereof. This Agreement may not be modified or cancelled in any manner except by a writing signed by both Employee and an authorized Company official.  Employee acknowledges that the Company has made no promises to Employee other than those in this Agreement.

 

b.               This Agreement shall extend to, be binding upon, and inure to the benefit of the parties and, as applicable, their respective successors, assigns, heirs and personal representatives.

 

c.                This Agreement may be executed simultaneously in counterparts, each of which shall be deemed an original and that a signed, facsimile or scanned email version of this Agreement shall be treated as a true and correct original and be legally enforceable.

 

8



 

IN WITNESS WHEREOF, and intending to be legally bound hereby, the Employee and the Company have executed this Permanent Release and Severance Agreement, totaling nine (9) pages, as set forth below.

 

/s/ Sean Whelan

 

October 25, 2016

EMPLOYEE

 

Date of Execution by Employee

 

 

 

/s/ Philip Hagerman

 

October 25, 2016

 

 

Date of Execution by the Company

 

 

 

Diplomat Pharmacy, Inc.

 

 

 

ELECTION TO EXECUTE PRIOR TO EXPIRATION OF
TWENTY-ONE DAY CONSIDERATION PERIOD
(To be signed only if Permanent Release and Severance Agreement is signed
prior to expiration of 21 days after it is presented to employee)

 

I understand that I have up to twenty-one (21) days within which to consider and execute the foregoing Permanent Release and Severance Agreement.  However, after having had sufficient time to consider the matter and to consult with counsel, I have freely and voluntarily elected to execute the Permanent Release and Severance Agreement before the twenty-one (21) day period has expired.

 

/s/ Sean Whelan

 

Sean Whelan

 

 

 

Date:

October 25, 2016

 

 

9


Exhibit 99.1

 

 

FOR IMMEDIATE RELEASE:

INVESTOR CONTACT:

Oct. 25, 2016

Bob East, Westwicke Partners

 

443.213.0500 | diplomat@westwicke.com

 

 

 

MEDIA CONTACT:

Jenny Cretu, Diplomat

810.768.9370 | jcretu@diplomat.is

 

Diplomat Announces Changes to Executive Team

 

The nation’s largest independent specialty pharmacy announces a new president and a transition of its chief financial officer.

 

FLINT, Mich. — Diplomat Pharmacy, Inc. (NYSE: DPLO) today announced that Paul Urick has been promoted to Diplomat’s president, effective Nov. 1, 2016.

 

Gary Kadlec will retire on Dec.31, 2016 and will continue to serve on Diplomat’s Board of Directors through his term. Kadlec has served as Diplomat’s president since June 2012 and as a director of Diplomat since February 2013. Under Kadlec’s day-to-day leadership, Diplomat has grown through its initial public offering, strategic acquisitions, organic growth, and a continued focus on operational innovation. Kadlec’s retirement will bring to close a remarkable health care career of nearly 45 years.

 

“As Diplomat continues to evolve in this rapidly developing industry, one thing that will never change is our relentless drive to make treatment as effective as possible and help our patients thrive,” said Phil Hagerman, CEO and chairman. “Gary has guided us with his strategic leadership, integrity, and unwavering commitment to our strong culture of patient care. As part of internal succession planning activities, Gary, Paul, and I have worked closely together to position the company for continued growth. As Paul takes the helm, he not only brings over two decades of in-depth knowledge and key relationships in specialty pharmacy, managed markets, and integrated health systems, he also embodies Diplomat’s core values.”

 

Urick previously served as Diplomat’s senior vice president of industry relations, pharmaceutical account management, and payor strategy. Prior, Urick served as senior vice president of pharmacy operations for Cigna Corporation. Earlier in his career, Urick held the position of senior vice president of pharmacy services at Independence Blue Cross where he incorporated and led FutureScripts and FutureScripts Secure LLC, two pharmacy benefit management companies he created. Urick also spent 10 years at Geisinger Health System, a leading integrated health system, where he transformed and insourced pharmacy benefit management operations for Geisinger Health Plan.

 



 

“I am delighted to work even more closely with our industry partners, operations, clinical services, and sales teams,” said Urick. “I look forward to driving continued innovation, growth, and leading Diplomat during this remarkable time.”

 

The company also announced that Sean Whelan will step down from his role as chief financial officer and a director on Diplomat’s Board of Directors, effective Dec. 31, 2016, to spend more time with his family. Robin Johnson, vice president of finance and chief financial officer of Diplomat’s Specialty Infusion Division, will take on an expanded leadership role until a formal replacement has been appointed. The Board of Directors is conducting a nationwide search for a permanent chief financial officer. Over the next two months, Whelan will work closely with Johnson to ensure a smooth transition. Johnson joined Diplomat in April 2015 with the acquisition of BioRx, and brings significant financial leadership and health care experience as the former chief financial officer of Vohra Health Services and vice president and chief accounting officer of Vitas Healthcare.

 

“Sean has played a central role in many of Diplomats major initiatives, including leading its initial public offering in October 2014, to help position Diplomat for the future. As chief financial officer of Diplomat for the past six years and a member of the Board of Directors for nearly five years, Sean has provided exceptional oversight and guidance, enabling us to focus on delivering the best solutions for our patients and our partners. We thank Sean for his many contributions to Diplomat as well as his ongoing commitment as he transitions into the next stage of his life,” Hagerman said.

 

To learn more about Diplomat, visit diplomat.is.

 

About Diplomat

 

Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit diplomat.is.

 

###